Skip to main content

Peer Review reports

From: Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial

Original Submission
5 Dec 2021 Submitted Original manuscript
8 Dec 2021 Author responded Author comments - Zhaoqing Tang
Resubmission - Version 2
8 Dec 2021 Submitted Manuscript version 2
11 Dec 2021 Reviewed Reviewer Report
14 Dec 2021 Reviewed Reviewer Report
27 Dec 2021 Reviewed Reviewer Report - Thomas Karasic
31 Dec 2021 Reviewed Reviewer Report - Valeria Merz
27 Jan 2022 Author responded Author comments - Zhaoqing Tang
Resubmission - Version 3
27 Jan 2022 Submitted Manuscript version 3
13 Feb 2022 Reviewed Reviewer Report - Thomas Karasic
14 Feb 2022 Reviewed Reviewer Report
16 Feb 2022 Author responded Author comments - Zhaoqing Tang
Resubmission - Version 4
16 Feb 2022 Submitted Manuscript version 4
Publishing
21 Feb 2022 Editorially accepted
6 Apr 2022 Article published 10.1186/s12916-022-02309-0

You can find further information about peer review here.

Back to article page